Premium
Ardelyx Inc (ARDX)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -50,90k | 304,83k | Automatic Disposition | 5,99 | 378,20k | -11,86% |
| 2026-06-18 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -31,00k | 154,97k | Derivative Exercise and Sale | 0,99 - 5,99 | 378,20k | - |
| 2026-06-15 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 118,17k | Automatic Disposition | 5,67 | 1,72M | -1,19% |
| 2026-06-15 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 97,55k | Derivative Exercise and Sale | 0,99 - 5,67 | 1,72M | - |
| 2026-05-21 | Mr. Joseph ReillySenior VP of Finance & Principal Accounting Officer | -3,72k | 23,31k | Vente | 6,27 | 149,84k | -2,42% |
| 2026-05-21 | Ms. Sue HohenleitnerCFO | -1,46k | 9,12k | Vente | 6,27 | 229,08k | -0,63% |
| 2026-05-21 | Dr. John E. BishopInitié | -2,31k | 14,45k | Vente | 6,27 | 336,85k | -0,68% |
| 2026-05-21 | Mr. James P. BradyChief HR Officer | -1,85k | 11,57k | Vente | 6,27 | 261,07k | -0,70% |
| 2026-05-21 | Mr. Eric Duane FosterChief Commercial Officer | -8,00k | 50,13k | Vente | 6,27 | 417,97k | -1,88% |
| 2026-05-21 | Mr. Mike KelliherChief Business Officer | -7,25k | 45,43k | Vente | 6,27 | 357,42k | -1,99% |
| 2026-05-21 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -6,99k | 43,80k | Vente | 6,27 | 429,09k | -1,60% |
| 2026-05-21 | Mr. Michael G. RaabPresident, CEO & Director | -54,75k | 343,13k | Vente | 6,27 | 1,75M | -3,04% |
| 2026-05-15 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 110,18k | Derivative Exercise and Sale | 0,99 - 6,28 | 1,80M | - |
| 2026-05-15 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 130,81k | Automatic Disposition | 6,28 | 1,80M | -1,14% |
| 2026-04-15 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 110,35k | Derivative Exercise and Sale | 0,99 - 6,29 | 1,82M | - |
| 2026-04-15 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 130,98k | Automatic Disposition | 6,29 | 1,82M | -1,13% |
| 2026-03-16 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 101,04k | Derivative Exercise and Sale | 0,99 - 5,84 | 1,84M | - |
| 2026-03-16 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 121,66k | Automatic Disposition | 5,84 | 1,84M | -1,12% |
| 2026-02-24 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 109,69k | Derivative Exercise and Sale | 0,99 - 6,26 | 1,86M | - |
| 2026-02-24 | Mr. Michael G. RaabPresident, CEO & Director | -20,83k | 130,31k | Automatic Disposition | 6,26 | 1,86M | -1,11% |
| 2026-02-20 | Mr. David M. MottIndependent Chairman of the Board | 333,33k | 1,95M | Achat | 5,84 | 3,26M | 11,38% |
| 2026-02-20 | Dr. John E. BishopInitié | -3,18k | 18,59k | Vente | 5,70 - 5,87 | 214,82k | -1,46% |
| 2026-02-20 | Mr. Joseph ReillySenior VP of Finance & Principal Accounting Officer | -4,99k | 29,18k | Vente | 5,70 - 5,87 | 151,79k | -3,18% |
| 2026-02-20 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -8,18k | 47,80k | Vente | 5,71 - 5,87 | 436,08k | -1,84% |
| 2026-02-20 | Mr. James P. BradyChief HR Officer | -2,54k | 14,87k | Vente | 5,71 - 5,87 | 113,73k | -2,19% |
| 2026-02-20 | Ms. Sue HohenleitnerCFO | -2,03k | 11,89k | Vente | 5,71 - 5,87 | 230,53k | -0,87% |
| 2026-02-20 | Mr. Mike KelliherChief Business Officer | -9,60k | 56,10k | Vente | 5,71 - 5,87 | 364,67k | -2,56% |
| 2026-02-20 | Mr. Michael G. RaabPresident, CEO & Director | -45,98k | 268,84k | Vente | 5,70 - 5,87 | 1,88M | -2,38% |
| 2026-02-20 | Mr. Eric Duane FosterChief Commercial Officer | -10,44k | 61,03k | Vente | 5,70 - 5,87 | 425,97k | -2,39% |
| 2026-01-08 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -50,00k | 299,40k | Derivative Exercise and Sale | 0,99 - 6,98 | 361,56k | - |
| 2025-11-21 | Ms. Elizabeth A. GrammerInitié | -6,00k | 33,19k | Vente | 5,54 | 299,90k | -1,96% |
| 2025-11-21 | Mr. Michael G. RaabPresident, CEO & Director | -46,89k | 259,61k | Vente | 5,54 | 1,48M | -3,07% |
| 2025-11-21 | Mr. Mike KelliherChief Business Officer | -5,56k | 30,79k | Vente | 5,54 | 271,18k | -2,01% |
| 2025-11-21 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -6,43k | 35,58k | Vente | 5,54 | 359,90k | -1,75% |
| 2025-11-21 | Mr. Joseph ReillySenior VP of Finance & Principal Accounting Officer | -11,09k | 61,38k | Vente | 5,54 | 108,91k | -9,24% |
| 2025-11-21 | Mr. Eric Duane FosterChief Commercial Officer | -5,81k | 32,19k | Vente | 5,54 | 295,68k | -1,93% |
| 2025-08-21 | Mr. Mike KelliherChief Business Officer | -5,42k | 32,13k | Vente | 5,93 | 276,74k | -1,92% |
| 2025-08-26 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -50,00k | 256,55k | Derivative Exercise and Sale | 0,99 - 6,12 | 366,32k | - |
| 2025-08-26 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -30,00k | 183,63k | Vente | 6,12 | 366,32k | -7,57% |
| 2025-08-21 | Dr. Laura A. WilliamsChief Patient Officer & Interim Chief Medical Officer | -6,26k | 37,14k | Vente | 5,93 | 396,32k | -1,56% |
| 2025-08-21 | Mr. Justin A. RenzInitié | -7,04k | 41,74k | Vente | 5,93 | 409,05k | -1,69% |
| 2025-08-21 | Mr. Michael G. RaabPresident, CEO & Director | -45,69k | 271,00k | Vente | 5,93 | 1,53M | -2,90% |
| 2025-08-21 | Ms. Elizabeth A. GrammerInitié | -5,84k | 34,65k | Vente | 5,93 | 305,89k | -1,87% |
| 2025-08-21 | Mr. Eric Duane FosterChief Commercial Officer | -15,31k | 90,80k | Vente | 5,93 | 301,50k | -4,83% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
